A phase 1 trial of 8‐chloro‐adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics

This study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of 8‐chloro‐adenosine (8‐Cl‐Ado) in patients with relapsed/refractory acute myeloid leukemia (AML).

[1]  Xiwei Wu,et al.  Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism , 2022, Cancers.

[2]  Xiwei Wu,et al.  Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine , 2021, Journal of Hematology & Oncology.

[3]  C. Chen,et al.  8‐chloro‐adenosine activity in FLT3‐ITD acute myeloid leukemia , 2019, Journal of cellular physiology.

[4]  M. Keating,et al.  Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy , 2017, British journal of haematology.

[5]  Jianxiang Wang,et al.  High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis , 2014, PloS one.

[6]  M. Liedtke,et al.  Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia , 2014, Leukemia & lymphoma.

[7]  C. M. Stellrecht,et al.  ATP directed agent, 8-chloro-adenosine, induces AMP activated protein kinase activity, leading to autophagic cell death in breast cancer cells , 2014, Journal of Hematology & Oncology.

[8]  F. Ferrara,et al.  Acute myeloid leukaemia in adults , 2013, The Lancet.

[9]  Jennifer B Dennison,et al.  8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. , 2010, Blood.

[10]  K. Kaluarachchi,et al.  Intracellular Succinylation of 8-Chloroadenosine and Its Effect on Fumarate Levels* , 2010, The Journal of Biological Chemistry.

[11]  V. Gandhi,et al.  Preclinical activity of 8‐chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis , 2009, British journal of haematology.

[12]  Shuxing Zhang,et al.  Inhibition of ATP synthase by chlorinated adenosine analogue. , 2009, Biochemical pharmacology.

[13]  C. M. Stellrecht,et al.  Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. , 2007, Cancer research.

[14]  M. Keating,et al.  Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. , 2005, Blood.

[15]  C. M. Stellrecht,et al.  RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. , 2003, Cancer research.

[16]  V. Gandhi,et al.  8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. , 2001, Cancer research.

[17]  R. Chinery,et al.  8-Cl-adenosine-induced inhibition of colorectal cancer growth in vitro and in vivo. , 2000, Neoplasia.

[18]  M. Dowsett,et al.  Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  G. Peters,et al.  The antiproliferative effect of 8-chloro-adenosine, an active metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell cycle kinetics. , 1997, Biochemical pharmacology.

[20]  J. C. Stoof,et al.  Growth inhibition of human glioma cells induced by 8-chloroadenosine, an active metabolite of 8-chloro cyclic adenosine 3':5'-monophosphate. , 1992, Cancer research.

[21]  G. Tortora,et al.  Effects of 8-chloroadenosine 3',5'-monophosphate and N6-benzyl-cyclic adenosine 5'-monophosphate on cell cycle kinetics of HL-60 leukemia cells. , 1991, Cancer research.

[22]  R. Kessin,et al.  8-Chloroadenosine 3',5'-monophosphate inhibits the growth of Chinese hamster ovary and Molt-4 cells through its adenosine metabolite. , 1991, Cancer research.

[23]  G. Merlo,et al.  Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3',5'-cyclic monophosphate provides a biological means for control of human colon cancer cell growth. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[24]  N. Kröger,et al.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.